Digital health specialist Kry has teamed up with pharma group Novo Nordisk on the development of resources that can help people with obesity manage their condition and adhere to treatment.
Alnylam Pharma has made a name for itself, developing gene-silencing therapies for rare disorders, but its latest discovery could take it into a much larger category – metabolic and cardiov
Denmark's Novo Nordisk has been almost single-handedly rebuilding the market for drugs to treat obesity over the last few years with its GLP-1 agonist drugs
Novo Nordisk's rollout of obesity therapy Wegovy has been beset by production problems, but the company says these are being resolved and it now anticipates it will help drive obesity sales
Novo Nordisk's new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-ap
After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.